Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy

Massimo Lopez, Paola Papaldo, Luigi Di Lauro, Mario Barduagni, Carlo Federico Perno, Aldo Barduagni

Research output: Contribution to journalArticle

Abstract

43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.

Original languageEnglish
Pages (from-to)244-247
Number of pages4
JournalOncology
Volume40
Issue number4
DOIs
Publication statusPublished - 1983

Fingerprint

Mitomycin
Hormones
Breast Neoplasms
Drug Therapy
Leukopenia
Thrombocytopenia
Dyspnea
Anemia
Hypersensitivity
Lung
Therapeutics
Pharmaceutical Preparations

Keywords

  • Breast cancer
  • Chemotherapy
  • Mitomycin C

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy. / Lopez, Massimo; Papaldo, Paola; Di Lauro, Luigi; Barduagni, Mario; Perno, Carlo Federico; Barduagni, Aldo.

In: Oncology, Vol. 40, No. 4, 1983, p. 244-247.

Research output: Contribution to journalArticle

Lopez, M, Papaldo, P, Di Lauro, L, Barduagni, M, Perno, CF & Barduagni, A 1983, 'Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy', Oncology, vol. 40, no. 4, pp. 244-247. https://doi.org/10.1159/000225736
Lopez, Massimo ; Papaldo, Paola ; Di Lauro, Luigi ; Barduagni, Mario ; Perno, Carlo Federico ; Barduagni, Aldo. / Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy. In: Oncology. 1983 ; Vol. 40, No. 4. pp. 244-247.
@article{825811e224eb468eb344ac4299713e68,
title = "Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy",
abstract = "43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63{\%} of the patients, thrombocytopenia in 67{\%}, and anemia in 14{\%}. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.",
keywords = "Breast cancer, Chemotherapy, Mitomycin C",
author = "Massimo Lopez and Paola Papaldo and {Di Lauro}, Luigi and Mario Barduagni and Perno, {Carlo Federico} and Aldo Barduagni",
year = "1983",
doi = "10.1159/000225736",
language = "English",
volume = "40",
pages = "244--247",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Mitomycin C in patients with metastatic breast cancer refractory to hormone therapy and chemotherapy

AU - Lopez, Massimo

AU - Papaldo, Paola

AU - Di Lauro, Luigi

AU - Barduagni, Mario

AU - Perno, Carlo Federico

AU - Barduagni, Aldo

PY - 1983

Y1 - 1983

N2 - 43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.

AB - 43 patients with advanced breast cancer, resistant to conventional therapies, were treated with mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks. No response was observed. The most common side effect was myelotoxicity. Leukopenia occurred in 63% of the patients, thrombocytopenia in 67%, and anemia in 14%. Two episodes of acute dyspnea were observed which were thought to be pulmonary hypersensitivity reactions. This study does not suggest that mitomycin C is of value as second- or third-line treatment in metastatic breast cancer. It is likely that the drug could play a more important role in combination with other chemotherapeutic agents.

KW - Breast cancer

KW - Chemotherapy

KW - Mitomycin C

UR - http://www.scopus.com/inward/record.url?scp=0020523976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020523976&partnerID=8YFLogxK

U2 - 10.1159/000225736

DO - 10.1159/000225736

M3 - Article

C2 - 6408547

AN - SCOPUS:0020523976

VL - 40

SP - 244

EP - 247

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -